Latest Bionovo Inc. Stories
EMERYVILLE, Calif., March 30, 2012 /PRNewswire/ -- Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011. (Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO) "In 2011 we initiated our Phase 3 trial for Menerba for the treatment of menopausal hot flashes and enrollment in that trial has progressed very...
EMERYVILLE, Calif., March 28, 2012 /PRNewswire/ -- Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data. Menerba is Bionovo's oral botanical drug...
EMERYVILLE, Calif., March 12, 2012 /PRNewswire/ -- Bionovo, Inc. (OTCQB: BNVI) On March 12, 2012, Bionovo, Inc., entered into a securities purchase agreement with investors to purchase an aggregate of 14,231,696 shares of our common stock, par value $0.0001 per share (the "Common Shares"). The aggregate purchase price for the Common Shares is approximately $426,951. (Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO) Additionally, each Investor will receive a warrant...
EMERYVILLE, Calif., March 9, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) today announced that it will need to obtain substantial additional funding to achieve its objectives of internally developing drugs. The Company reduced its workforce by over 90%. The remaining management of the Company will receive reduced cash compensation until either adequate financing can be obtained or the Company is sold. The Company can not make any assurances about either of these...
EMERYVILLE, Calif., March 8, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that its President and Chief Medical Officer will be awarded as one of California's 14th Assembly District Women of the Year at an awards ceremony taking place on March 8, 2012. Dr. Tagliaferri is being honored for her notable accomplishments in...
EMERYVILLE, Calif., March 1, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that David Boyle, Chief Financial Officer and Senior Vice President, will be presenting at the Cowen and Company 32nd Annual Health Care Conference at 2:10 p.m. EST on March 5, 2012. The event will be held at the Boston Marriott Copley Place, in...
EMERYVILLE, Calif., Feb. 29, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) has recently filed a registration statement on Form S-1 with the Securities and Exchange Commission (File No. 33-179429) to register the offering of an aggregate of up to $25 million in convertible preferred stock and warrants to purchase shares of common stock. The convertible preferred stock to be issued in this offering shall be senior in rank to all shares of common stock of the Company...
EMERYVILLE, Calif., Feb. 21, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced its decision to explore strategic options. As a result of this decision, the Company has decided to delay the announcement of its financial results for the year ended December 31, 2011, previously planned for today, to a later date. The Company...
EMERYVILLE, Calif., Feb.16, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that it will host a conference call on Tuesday, February 21, 2012 at 1:30 PM PST to discuss its 2011 financial highlights for the year ended December 31, 2011. (Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO) Interested parties can...
EMERYVILLE, Calif., Feb. 7, 2012 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the publication of two studies that characterize the anticancer properties of its drug Bezielle, and that identify the active principles of the drug. The two papers are published in the Journal of the Public Library of Science One. (Logo:...
